Article
Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy.
The oncologist - 9 Mar 2026
Mercinelli Chiara, Pavlick Dean, Agarwal Neeraj, Spiess Philippe E, Li Roger, Kamat Ashish M, Grivas Petros, Gupta Shilpa, Maiorano Brigida Anna, Tateo Valentina, Cigliola Antonio, Piacentini Michela, Jacob Joseph M, Bratslavsky Gennady, Basnet Alina, Ross Jeffrey S, Necchi Andrea
Abstract excerpt
BACKGROUND: the homologous recombination deficiency signature (HRDsig) is emerging as a novel potential predictor of PARP-inhibitor (PARPi) response. We compared genomic alterations (GA) across BRCA2-loss, BRCA2 short variant-mutated (svmut), and BRCA2-wild type (wt) clinically advanced prostate carcinoma (CAPC) samples, combined with an assessment of HRDsig status to gain a better understanding of these...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.